



(12) Translation of
European patent specification

(11) NO/EP 2975051 B1

NORWAY

(19) NO
(51) Int Cl.
C07K 16/06 (2006.01)
A61K 39/00 (2006.01)
C07K 16/24 (2006.01)
C07K 16/28 (2006.01)
C07K 16/46 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2021.06.28
(80)	Date of The European Patent Office Publication of the Granted Patent	2021.04.14
(86)	European Application Nr.	15181155.1
(86)	European Filing Date	2010.06.25
(87)	The European Application's Publication Date	2016.01.20
(30)	Priority	2009.06.26, US, 220687 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA
(72)	Inventor	DAVIS, Samuel, 332 West 88th Street Apt. B2, New York, NY 10024, USA SMITH, Eric, 310 Lexington Avenue Apt. 4E, New York, NY 10016, USA MACDONALD, Douglas, 260 West End Avenue Apt. 10C, New York, NY 10023, USA OLSON, Kara Louise, 30 Prospect Street, White Plains, NY 10605, USA
(74)	Agent or Attorney	BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54)	Title	READILY ISOLATED BISPECIFIC ANTIBODIES WITH NATIVE IMMUNOGLOBULIN FORMAT
(56)	References Cited:	DE-C1- 4 419 399, US-A1- 2002 051 780, US-A- 5 945 311 S. IBRAHIM ET AL: "Immunoglobulin Binding Specificities of the Homology Regions (Domains) of Protein A", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 38, no. 4, 1 October 1993 (1993-10-01), pages 368-374, XP55123876, ISSN: 0300-9475, DOI: 10.1111/j.1365-3083.1993.tb01739.x Melissa A Starovasnik ET AL: "Antibody variable region binding by Staphylococcal protein A: Thermodynamic analysis and location of the Fv binding site on E-domain", PRS, 1 July 1999 (1999-07-01), pages 1423-1431, XP055123878, Bristol DOI: 10.1110/ps.8.7.1423 Retrieved from the Internet: URL: http://onlinelibrary.wiley.com/doi/10.1110/ps.8.7.1423/abstract JENDEBERG L ET AL: "Engineering of Fc1 and Fc3 from human immunoglobulin G to analyse

subclass specificity for staphylococcal protein A", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 201, no. 1, 14 February 1997 (1997-02-14), pages 25-34, XP004050039, ISSN: 0022-1759, DOI: 10.1016/S0022-1759(96)00215-3

DUHAMEL R C ET AL: "PH GRADIENT ELUTION OF HUMAN IMMUNO GLOBULIN G-1 IMMUNO GLOBULIN G-2 AND IMMUNO GLOBULIN G-4 FROM PROTEIN A SEPHAROSE", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 31, no. 3-4, 1 January 1979 (1979-01-01), pages 211-217, XP002477308, ISSN: 0022-1759, DOI: 10.1016/0022-1759(79)90133-9

MARTIN ET AL: "Separation of guinea pig IgG subclasses by affinity chromatography on protein A-Sepharose", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 52, no. 2, 30 July 1982 (1982-07-30), pages 205-212, XP023675663, ISSN: 0022-1759, DOI: 10.1016/0022-1759(82)90046-1 [retrieved on 1982-07-30]

ROBEN P W ET AL: "VH3 family antibodies bind domain D of staphylococcal protein A", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 154, no. 12, 15 June 1995 (1995-06-15), pages 6437-6445, XP002508063, ISSN: 0022-1767

VAN LOGHEM E ET AL: "Staphylococcal protein A and human IgG subclasses and allotypes", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, BLACKWELL SCIENCE PUBL., OXFORD, GB, vol. 15, no. 3, 1 March 1982 (1982-03-01), pages 275-278, XP008112756, ISSN: 0300-9475

LINDHOFER H ET AL: "Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 155, no. 1, 1 July 1995 (1995-07-01), pages 219-225, XP002190775, ISSN: 0022-1767

MARTIN ET AL: "Chromatographic fractionation of rhesus monkey (Macaca mulatta) IgG subclasses using DEAE cellulose and protein A-Sepharose", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 50, no. 3, 14 May 1982 (1982-05-14), pages 319-329, XP023676309, ISSN: 0022-1759, DOI: 10.1016/0022-1759(82)90170-3 [retrieved on 1982-05-14]

DEISENHOFER J: "CRYSTALLOGRAPHIC REFINEMENT AND ATOMIC MODELS OF A HUMAN FC FRAGMENT AND ITS COMPLEX WITH FRAGMENT B OF PROTEIN A FROM STAPHYLOCOCCUS AUREUS AT 2.9- AND 2.8-AA RESOLUTION", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, US LNKD- DOI:10.1021/BI00512A001, vol. 20, no. 9, 28 April 1981 (1981-04-28) , pages 2361-2370, XP009051337, ISSN: 0006-2960

LINDMARK R ET AL: "Binding of immunoglobulins to protein A and immunoglobulin levels in mammalian sera", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL LNKD- DOI:10.1016/0022-1759(83)90104-7, vol. 62, no. 1, 1 January 1983 (1983-01-01), pages 1-13, XP023676342, ISSN: 0022-1759 [retrieved on 1983-01-01]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Fremgangsmåte for å isolere et bispesifikt antistoff, fremgangsmåten omfatter å isolere det bispesifikke antistoffet ved anvendelse av en protein A-affinitetsbærer og å anvende en pH-gradient i nærvær av et ionisk modifierende middel i en konsentrasjon på 0,15 M - 1,0 M; hvor det ionisk modifierende middelet er et kloridsalt av et alkalimetall eller et jordalkalimetall; hvor det bispesifikke antistoffet omfatter to tungkjeder som gjenkjenner to forskjellige epitoper eller to forskjellige antigener og to lettkjeder som har identiske variable og konstante domener; hvor CH3-domenet til en av tungkjedene er valgt fra gruppen bestående av SEKV ID NR: 1, SEKV ID NR: 3, og SEKV ID NR: 5 og CH3-domenet til den andre tungkjeden er valgt fra gruppen bestående av SEKV ID NR: 2, SEKV ID NR: 4, og SEKV ID NR: 6.
2. Fremgangsmåte ifølge et hvilket som helst av de ovennevnte kravene, hvor det ionisk modifierende middelet er NaCl, KCl, LiCl, CaCl₂, eller MgCl₂.
3. Fremgangsmåte ifølge et hvilket som helst av de ovennevnte kravene, hvor det ioniske modifierende middelet er til stede i en konsentrasjon på 0,15 M til 0,5 M eller i en konsentrasjon på 0,5 M til 1 M.
4. Fremgangsmåte ifølge et hvilket som helst av de ovennevnte kravene, hvor pH-gradienten er fra pH 3,9 til pH 4,5, eller fra pH 4,0 til pH 4,4, eller fra pH 4,1 til pH 4,3, eventuelt hvor gradienten er en lineær gradient.